MTOR and breast cancer: Deng et al. (2018); Liu et al. (2016a); Liu et al. (2016b) Wedelolactone inhibited breast cancer-mediated osteoclastogenesis and OC activity in CD14+ monocytes through the AKT-mTOR pathway to treat bone metastasis after breast cancer. Hsieh et al. (2015).